Castle Biosciences logo
Castle Biosciences
CSTL | NASDAQ
Chart Builder DCF Calculator
$32.75
-$1.04 (-3.08%)
At close: Nov 16, 2026, 4:00 PM ET
$32.75
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Castle Biosciences Company Profile

Company profile explained

Company Profile

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.

Key Executives

Name Position
Derek J. Maetzold Founder, Chief Executive Officer, President & Director
Frank Stokes Chief Financial Officer & Treasurer
Kristen Oelschlager Chief Operating Officer
Camilla Zuckero Vice President of Investor Relations & Corporate Affairs
Hillary Caruso Chief of Staff
Jay Braxton Senior Vice President of Marketing
Keli Greenberg Vice President of Human Resources
Kevin Doman Senior Vice President of Sales
Matthew Goldberg Senior Vice President of Medical
Tobin W. Juvenal Chief Commercial Officer
Trisha Poteet Senior VP of Clinical Services & Manufacturing Operations

Latest SEC Filings

Date Type Title
Oct 30, 2026 4 Filing
Oct 29, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 28, 2026 4 Filing
Oct 21, 2026 4 Filing
Oct 14, 2026 4 Filing
Oct 07, 2026 4 Filing
Oct 05, 2026 4 Filing
Oct 01, 2026 4 Filing
Sep 23, 2026 4 Filing
Sep 16, 2026 4 Filing
View All SEC Filings ➞
Castle Biosciences
Castle Biosciences logo
Country United States
IPO Date Jul 25, 2019
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 1,002
CEO Derek J. Maetzold

Contact Details

1500 W. Parkwood Ave Friendswood, Texas 77546 United States

Stock Details

Ticker Symbol CSTL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001447362
CUSIP Number 14843C105
ISIN Number US14843C1053
SIC Code 8071

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.